Introduction
============

Gastric cancer has the second highest prevalence and the third highest mortality rate among cancers in Korea \[[@b1-ce-2018-006]\]. Since population-based screening for gastric cancer in Korea was implemented in 2002, either endoscopy or gastrography is recommended every 2 years for adults aged 40 years or older \[[@b2-ce-2018-006]\]. Population-based screening seems to be effective in reducing mortality from gastric cancer in Korea \[[@b2-ce-2018-006]\]. The participation rate in the Korean National Cancer Screening Program (KNCSP) was 47.3% in 2012 \[[@b3-ce-2018-006]\]. In previous studies, endoscopic screening was more closely associated with diagnosis of early gastric cancer (EGC) than was upper-gastrointestinal series (UGIS) screening \[[@b4-ce-2018-006],[@b5-ce-2018-006]\], and the participation rate in surveillance endoscopy for gastric cancer increased from 31% in 2002 to 73% in 2011 \[[@b6-ce-2018-006]\]. Recently, the number of patients who undergo curative treatment by endoscopic resection has also increased \[[@b7-ce-2018-006]\]. Endoscopic resection of EGC might not be inferior to surgery with respect to overall survival \[[@b8-ce-2018-006]\]. Moreover, early detection of gastric cancer for curative treatment by endoscopic resections resulted in better prognosis and better quality of life by preserving the stomach \[[@b9-ce-2018-006],[@b10-ce-2018-006]\]. Prediction of curative endoscopic resection of EGC is becoming increasingly important because the general population is aging, and quality of life after treatment is becoming a greater consideration.

Therefore, it is necessary to investigate the factors predicting curative endoscopic resection of EGC. Although symptoms/signs such as anemia and weight loss are well-known factors related to gastric cancer \[[@b11-ce-2018-006]\], most patients with EGC are asymptomatic \[[@b11-ce-2018-006]\]. Patients undergoing endoscopic examination performed in accordance with alarm symptoms/signs are often found to have an advanced stage of gastric cancer and are not curable \[[@b12-ce-2018-006]\]. Moreover, these alarm symptoms/signs are not meaningful for early detection of gastric cancer or for predicting curative endoscopic resection of EGC \[[@b12-ce-2018-006]\].

We designed this study to investigate factors predicting curative endoscopic resection of EGC in the era of population-based screening. We also assessed the effect of surveillance testing for gastric cancer on the prognosis.

Materials and Methods
=====================

Patients
--------

We retrospectively reviewed collected data of patients with newly diagnosed gastric cancer who underwent treatment at Seoul St. Mary's Hospital between May 2011 and May 2016. All patients provided informed consent. We conducted a questionnaire survey and reviewed medical records of patients. Patients who refused to participate in the survey or who did not complete the questionnaire were excluded. In addition, patients who underwent surveillance testing within 6 months before the diagnosis of gastric cancer were excluded due to the probability of misdiagnosis. This study was approved by the institutional review board of Seoul St. Mary's Hospital (IRB approval number: KC11EISE0239).

Data collection
---------------

The questionnaires included questions about symptoms, social history, family history, experience participating in KNCSP, reasons for not participating in KNCSP, knowledge about KNCSP, experience of endoscopy or gastrography before diagnosis of gastric cancer, surveillance test intervals and reasons for undergoing examinations. The interval between the last and penultimate surveillance test before diagnosis of gastric cancer was classified as \>6 months to ≤18 months (1-year interval), \>18 months to ≤30 months (2-year interval) and \>30 months (over 2-year interval).

We obtained additional data by reviewing medical records. These data included initial hemoglobin level, and *Helicobacter pylori* status. Specimens were taken from the gastric mucosa of each patient to confirm *H. pylori* infection status. These samples were used for histology by modified Giemsa staining, rapid urase test (CLOtest®; HALYARD, Zaventem, Belgium), *H. pylori* polymerase chain reaction, and *H. pylori*-specific IgG (Enzygost; Dade Behring, Marburg, Germany). Positive results in one or more tests designated the presence of *H. pylori* infection \[[@b13-ce-2018-006]\]. The specimens of endoscopic or surgical resection from patients with gastric cancer were evaluated according to gross and histological features, tumor size, and lymph node metastasis stage as defined by the American Joint Committee on Cancer Cancer Staging Manual, 7th edition \[[@b14-ce-2018-006]\]. We defined differentiated and undifferentiated gastric adenocarcinoma using the Japanese classification system \[[@b15-ce-2018-006]\].

Outcomes and treatment modalities
---------------------------------

The indications of endoscopic submucosal dissection (ESD) in our institution are as follows: (1) differentiated intramucosal adenocarcinoma without ulceration, irrespective of tumor size (2) undifferentiated intramucosal cancer \<1 cm without ulceration (3) absence of lymph node involvement and distant metastasis in abdominal computed tomography (4) no submucosal invasive findings using endoscopy and/or endoscopic ultrasonography. Group 1 was defined as patients who underwent endoscopic resection according to the indications as described above and pathologically confirmed curative resection. The curative resection was defined as en bloc resection, pT1a, negative horizontal and vertical margin, and no lymphovascular infiltration. Group 2 was defined as patients undergoing surgical resection and pathologically confirmed curative resection. In addition, patients with beyond indications after ESD were classified into Group 2. Group 3 was defined as patients with distant metastasis or pathologically non-curative resection after surgical treatment.

Statistical analysis
--------------------

We used statistical tests, such as analysis of variance, χ^2^ test, and Fisher's exact test to compare results. Descriptive statistics of continuous variables were represented as mean±standard deviation. We conducted logistic regression analysis to estimate the odds ratio (OR) for associations between the treatment groups described above and factors of age, sex, first-degree relatives with gastric cancer, weight loss, and screening interval. Significant differences between the groups were defined as *p*-value \<0.05. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).

Results
=======

Clinicopathologic characteristics
---------------------------------

A total of 2,868 patients were newly diagnosed and started treatment for stomach cancer at Seoul St. Mary's Hospital between May 2011 and May 2016. A total of 512 patients participated in our study and completed questionnaires. Among them, 35 patients were excluded due to incomplete questionnaires and eight patients who underwent endoscopy within 6 months before the diagnosis of gastric cancer were excluded to avoid misdiagnosis. The remaining 469 patients were enrolled in the study. Of these, 147 (31.3%) were in Group 1, 260 (55.4%) were in Group 2, and 62 (13.3%) were in Group 3.

Patient age, history of first degree relatives with stomach cancer, history of previous malignancy, *H. pylori* infection status were noted. Body mass index and proportion of male patients were lower in Group 3 than Group 1 or 2. Regular gastric cancer surveillance with a 2-year interval before the diagnosis of stomach cancer was most common in Group 1. More cases of differentiated histology were observed in Group 1, conversely, more cases of undifferentiated histology were observed in Group 3 ([Table 1](#t1-ce-2018-006){ref-type="table"}).

Gastrointestinal and alarm symptoms/signs
-----------------------------------------

[Table 2](#t2-ce-2018-006){ref-type="table"} shows gastrointestinal symptoms and alarm symptoms/signs at diagnosis. Although gastrointestinal symptoms/signs were seen in Groups 1 and 2, they were most frequently observed in Group 3. Well-known alarm symptoms/signs associated with gastric cancer such as gastrointestinal bleeding, initial hemoglobin and clinically important weight loss (defined as unintentional weight loss of more than 5% of usual body weight over 12 months) were rarely observed in Group 1.

Effect of surveillance testing on the prognosis of gastric cancer
-----------------------------------------------------------------

Multivariate analysis was performed to investigate factors predicting curative endoscopic resection. Patient age, sex, history of first degree relative with stomach cancer, initial hemoglobin, and weight loss did not affect the prognosis of gastric cancer. Regular surveillance testing for gastric cancer was an independent factor predicting curative endoscopic resection (OR, 6.099; 95% confidence interval \[CI\], 2.532--14.933) ([Table 3](#t3-ce-2018-006){ref-type="table"}).

The surveillance interval, surveillance method for gastric cancer, reasons for surveillance, and knowledge of KNCSP were compared among the groups ([Table 4](#t4-ce-2018-006){ref-type="table"}). Experience participating in KNCSP and experience with endoscopy or gastrography before diagnosis were more common in Group 1 than in Group 2 or Group 3. Regular check-up was the main reason for examination in Group 1, while symptoms were the main reason in Group 3. There was no difference in the surveillance method among the three groups, and approximately 90% of the patients were diagnosed with stomach cancer through endoscopy. The surveillance interval was shortest in Group 1, and more patients in Group 3 lacked experience of surveillance testing.

Logistic regression models were performed with adjustment for possible confounding variables of age, sex, first degree relatives with stomach cancer, smoking history, weight loss, and initial hemoglobin to determine the effect of the interval of surveillance test on endoscopic curative resection of EGC ([Table 5](#t5-ce-2018-006){ref-type="table"}). Patients undergoing gastric cancer screening had a significantly higher rate of endoscopic curative resection compared with subjects who had never been screened. The ratio of endoscopic curative resection was not significantly different between surveillance intervals of 1 year, 2 years and more than 2 years. However, compared with never-screened patients, the adjusted ORs for curative endoscopic resection tended to increase as the interval of surveillance test decreased. In addition, the patients receiving 1-year surveillance screening had a significantly higher rate of endoscopic resection than patients who had no surveillance test within 3 years (OR, 12.746; 95% CI, 4.587--35.418; *p*\<0.001). There was a significant dose-response relationship between surveillance interval and the rate of curative endoscopic resection (Cochran-Armitage Trend Test, *p*\<0.0001). In other words, shorter the screening test interval, higher the rate of endoscopic curative resection.

Discussion
==========

Our study investigated the factors predicting curative endoscopic resection of EGC compared with surgical or palliative treatment. Most patients with endoscopic curative resection had minimal abdominal symptoms and fewer alarming symptoms/signs. Regular surveillance endoscopy for gastric cancer was an independent factor predicting curative endoscopic resection of gastric cancer.

Most patients with endoscopic curative resection had minimal abdominal symptoms and fewer alarm symptoms/signs, since 90% of the patients with curative endoscopic resection had regular check-ups. Anemia is considered a well-known predictor of gastric cancer \[[@b16-ce-2018-006]\], but it was present in only 2% of patients in Group 1 in our study. Many previous studies revealed that endoscopic examination after identifying symptoms did not help in earlier detection of gastric cancer \[[@b11-ce-2018-006],[@b12-ce-2018-006]\]. Surveillance testing by endoscopy and gastrography reduced the mortality rates associated with gastric cancer and increased the detection rate of EGC \[[@b17-ce-2018-006],[@b18-ce-2018-006]\]. In our study, regular surveillance testing for gastric cancer was an independent factor predicting the curative endoscopic resection of EGC. We could not measure the cancer-related mortality rate, which is the gold standard for measuring the effect of early screening and treatment. However, according to recent studies, long-term outcomes of endoscopic resection for EGC are similar to those of surgical resection, and endoscopic resection might provide better quality of life to patients \[[@b9-ce-2018-006],[@b10-ce-2018-006]\].

Regular surveillance testing for gastric cancer could detect early lesions suitable for endoscopic resection and avoid invasive surgery. Population-based screening programs for gastric cancer have been established in Korea and Japan \[[@b4-ce-2018-006],[@b19-ce-2018-006]\]. The KNCSP recommends biennial endoscopic screening for gastric cancer in Korea, and detection of localized gastric cancer is more likely in patients who have been screened compared with never-screened patients \[[@b5-ce-2018-006]\]. We found that a 1-year interval of surveillance testing for gastric cancer increased the rate of curative endoscopic resection of EGC compared with a 2-year interval. We expect that more frequent surveillance testing would increase both the rate of detection of EGC and the rate of curative endoscopic resection of EGC. These results are similar to those of other studies conducted in Korea \[[@b20-ce-2018-006]-[@b22-ce-2018-006]\]. In a recent study, within the KNCSP, patients who underwent an upper endoscopy were less likely to die from gastric cancer, and no associations were found with UGIS \[[@b23-ce-2018-006]\]. In contrast, some studies demonstrated that frequent endoscopic surveillance for gastric cancer did not reduce cancer-related mortality \[[@b24-ce-2018-006]\]. In addition, frequent endoscopic surveillance of gastric cancer for all patients might not be cost effective \[[@b25-ce-2018-006]\]. However, the difference in mortality rate according to interval of endoscopic surveillance for gastric cancer has not been well defined. In addition, few studies have been performed using the interval at which endoscopic resection is possible. Most of the group 1 patients underwent screening for regular check-up, not due to alarming symptoms. Some patients of group 1 might have been at high risk and may have been recommended to visit at 1 year intervals. However, we did not investigate the reasons for testing at more frequent annual intervals than national guidelines. Further refinement of the high-risk group is required for gastric cancer that requires a shorter interval of surveillance testing, such as patients with atrophic gastritis or intestinal metaplasia, family history of gastric cancer and previously diagnosed gastric cancer \[[@b26-ce-2018-006],[@b27-ce-2018-006]\]. Further evaluation is necessary regarding the cost-effectiveness of more frequent endoscopic surveillance for gastric cancer.

This study has several limitations. First, because of the staged work-up through various pathways at our institution prior to treatment, we could obtain informed consents of only 512 of the 2,868 patients (17.9%). Most of the enrolled patients were those who visited internal medicine department. This study population did not represent all the patients diagnosed with gastric cancer at our hospital, which might lead to a bias. Second, we have included patients who belong to the expanded criteria for ESD. The selection of treatment options for these patients has not yet been established.

In conclusion, regular surveillance testing was an independent factor predicting curative endoscopic resection of gastric cancer. More frequent surveillance testing could help in early detection of gastric cancers, with a chance of endoscopic curative resection.
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###### 

Clinicopathologic Characteristics of Patients according to Outcome and Treatment Modality for Gastric Cancer

                                                                      Group 1^[a)](#tfn1-ce-2018-006){ref-type="table-fn"}^ (*n*=147)   Group 2^[b)](#tfn2-ce-2018-006){ref-type="table-fn"}^ (*n*=260)   Group 3^[c)](#tfn3-ce-2018-006){ref-type="table-fn"}^ (*n*=62)   *p*-value
  ------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------- -----------
  Age (mean±SD)                                                       62.6±10.6                                                         60.2±11.5                                                         61.2±10.4                                                        0.149
  Sex, Male                                                           107 (72.8%)                                                       162 (62.3%)                                                       36 (58.1%)                                                       0.048
  BMI, kg/m^2^ (mean±SD)                                              23.9±2.8                                                          22.9±3.3                                                          21.5±2.8                                                         \<0.001
  History of first degree relatives with stomach cancer               35 (23.8%)                                                        64 (24.6%)                                                        10 (16.1%)                                                       0.357
  History of previous malignancy                                      17 (11.6%)                                                        25 (9.6%)                                                         6 (9.7%)                                                         0.127
   None                                                               130 (88.4%)                                                       235 (90.4%)                                                       56 (90.3%)                                                       
   Colorectal                                                         8 (5.4%)                                                          3 (1.2%)                                                          1 (1.6%)                                                         
   Esophagus                                                          3 (2.0%)                                                          1 (0.4%)                                                          0 (0.0%)                                                         
   Lung                                                               1 (0.7%)                                                          1 (0.4%)                                                          0 (0.0%)                                                         
   Liver                                                              1 (0.7%)                                                          2 (0.8%)                                                          1 (1.6%)                                                         
   Breast                                                             1 (0.7%)                                                          2 (0.8%)                                                          2 (3.2%)                                                         
   Others                                                             3 (2.0%)                                                          16 (6.2%)                                                         2 (3.2%)                                                         
  *H. pylori* infection status                                        88/141 (62.4%)                                                    109/162 (67.3%)                                                   22/30 (73.3%)                                                    0.442
  Experience of regular gastric cancer surveillance (2-yr interval)   101 (70.6%)                                                       128 (49.6%)                                                       17 (27.4%)                                                       \<0.001
   Unknown^[d)](#tfn4-ce-2018-006){ref-type="table-fn"}^              4                                                                 2                                                                 0                                                                
  Differentiated stomach cancer                                       139 (94.6%)                                                       124 (47.7%)                                                       17 (27.4%)                                                       \<0.001
  Stage                                                                                                                                                                                                                                                                    \<0.001
   I                                                                  147 (100%)                                                        194 (74.6%)                                                       0 (0 %)                                                          
   II                                                                 0 (0%)                                                            28 (10.8%)                                                        3 (4.8%)                                                         
   III                                                                0 (0%)                                                            38 (14.6%)                                                        4 (6.5%)                                                         
   IV                                                                 0 (0%)                                                            0 (0%)                                                            55 (88.7%)                                                       

SD, standard deviation; BMI, body mass index; *H. pylori*, *Helicobacter pylori*.

Patients undergoing endoscopic resection and pathologically confirmed curative resection.

Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection.

Patients with distant metastasis or pathologically non-curative resection after surgical treatment.

Patients who could not remember the cancer surveillance interval were not included (*n*=6).

###### 

Comparison of Symptoms/Signs among the Group according to Outcome and Treatment Modality for Gastric Cancer

                                                                                   Group 1^[a)](#tfn5-ce-2018-006){ref-type="table-fn"}^ (*n*=147)   Group 2^[b)](#tfn6-ce-2018-006){ref-type="table-fn"}^ (*n*=260)   Group 3^[c)](#tfn7-ce-2018-006){ref-type="table-fn"}^ (*n*=62)   *p*-value
  -------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------- -----------
  Foreign body sensation                                                           17 (12.0%)                                                        31 (12.3%)                                                        10 (16.4%)                                                       0.653
  Dysphagia                                                                        11 (7.8%)                                                         13 (5.2%)                                                         8 (13.1%)                                                        0.085
  Odynophagia                                                                      2 (1.4%)                                                          7 (2.8%)                                                          5 (8.3%)                                                         0.032
  Postprandial satiety                                                             43 (30.7%)                                                        93 (36.9%)                                                        34 (55.7%)                                                       0.003
  Early satiety                                                                    17 (12.1%)                                                        59 (23.4%)                                                        33 (53.2%)                                                       \<0.001
  Heartburn                                                                        38 (27.0%)                                                        78 (30.8%)                                                        21 (34.4%)                                                       0.530
  Epigastric pain                                                                  21 (14.9%)                                                        59 (23.4%)                                                        20 (32.8%)                                                       0.014
  Nausea                                                                           21 (14.9%)                                                        39 (15.5%)                                                        21 (33.9%)                                                       0.002
  Vomiting                                                                         7 (5.0%)                                                          25 (10.0%)                                                        15 (24.6%)                                                       \<0.001
  Anorexia                                                                         13 (9.2%)                                                         53 (21.1%)                                                        32 (51.6%)                                                       \<0.001
  Dizziness                                                                        43 (30.5%)                                                        72 (28.2%)                                                        20 (32.3%)                                                       0.783
  Melena                                                                           13 (9.2%)                                                         33 (13.0%)                                                        16 (25.8%)                                                       0.006
  Hematochezia                                                                     2 (1.4%)                                                          6 (2.4%)                                                          2 (3.3%)                                                         0.681
  Hematemesis                                                                      0 (0.0%)                                                          5 (2.0%)                                                          5 (8.2%)                                                         0.001
  Clinically important weight loss^[d)](#tfn8-ce-2018-006){ref-type="table-fn"}^   18 (12.2%)                                                        58 (22.3%)                                                        36 (58.1%)                                                       \<0.001
  Initial Hb \<10 g/dL                                                             3 (2.0%)                                                          18 (6.9%)                                                         20 (32.3%)                                                       \<0.001

Hb, hemoglobin.

Patients undergoing endoscopic resection and pathologically confirmed curative resection.

Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection.

Patients with distant metastasis or pathologically non-curative resection after surgical treatment.

Unintentional weight loss of more than 5% of usual body weight over 12 months.

###### 

Factors Predicting Rate of Curative Endoscopic Resection of Early Gastric Cancer

  Factors                                                                                            Univariate analysis     Multivariate analysis                           
  -------------------------------------------------------------------------------------------------- ----------------------- ----------------------- ----------------------- ---------
  Age \<60                                                                                           1.141 (0.768--1.693)    0.514                   1.506 (0.673--3.369)    0.319
  Male                                                                                               1.675 (1.093--2.568)    0.018                   1.054 (0.479--2.321)    0.896
  Hb \>10 g/dL                                                                                       6.423 (1.949--21.162)   0.002                   3.447 (0.736--16.147)   0.116
  Absence of first degree relative with stomach cancer                                               0.955 (0.603--1.512)    0.844                   1.219 (0.509--2.918)    0.656
  Absence of clinically important weight loss^[a)](#tfn9-ce-2018-006){ref-type="table-fn"}^          2.611 (1.293--5.275)    0.007                   1.488 (0.671--3.300)    0.328
  Regular gastric cancer surveillance^[b)](#tfn10-ce-2018-006){ref-type="table-fn"}^ (within 2 yr)   2.902 (1.903--4.425)    \<0.001                 6.099 (2.532--14.933)   \<0.001

CI, confidence interval; Hb, hemoglobin.

Unintentional weight loss of more than 5% of usual body weight over 12 months.

Patients who could not remember the cancer surveillance interval were not included (*n*=6).

###### 

Comparison of Surveillance Screening among Groups according to Outcome and Treatment Modality for Gastric Cancer

                                                                         Group 1^[a)](#tfn11-ce-2018-006){ref-type="table-fn"}^ (*n*=147)   Group 2^[b)](#tfn12-ce-2018-006){ref-type="table-fn"}^ (*n*=260)   Group 3^[c)](#tfn13-ce-2018-006){ref-type="table-fn"}^ (*n*=62)   *p*-value
  ---------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------ ----------------------------------------------------------------- -----------
  Experience participating in KNCSP                                      90 (61.2%)                                                         156 (60.0%)                                                        26 (41.9%)                                                        0.022
  Experience with endoscopy or gastrography before diagnosis             133 (93.0%)                                                        183 (70.9%)                                                        32 (51.6%)                                                        \<0.001
  Reason for examination                                                                                                                                                                                                                                                         \<0.001
   Regular check up                                                      130 (88.4%)                                                        200 (76.9%)                                                        25 (40.3%)                                                        
   Symptom                                                               17 (11.6%)                                                         60 (23.1%)                                                         37 (59.7%)                                                        
  Surveillance method                                                                                                                                                                                                                                                            0.134
   Endoscopy                                                             118 (88.7%)                                                        147 (80.3%)                                                        27 (84.4%)                                                        
   Radiology                                                             15 (11.3%)                                                         36 (19.7%)                                                         5 (15.6%)                                                         
  Surveillance interval^[d)](#tfn14-ce-2018-006){ref-type="table-fn"}^                                                                                                                                                                                                           \<0.001
   1 yr                                                                  54 (37.8%)                                                         61 (23.6%)                                                         11 (17.7%)                                                        
   2 yr                                                                  47 (32.9%)                                                         67 (26.0%)                                                         6 (9.7%)                                                          
   Over 2 yr                                                             32 (22.4%)                                                         55 (21.3%)                                                         15 (24.2%)                                                        
   None                                                                  10 (7.0%)                                                          75 (29.1%)                                                         30 (48.4%)                                                        

KNCSP, Korean National Cancer Screening Program.

Patients undergoing endoscopic resection and pathologically confirmed curative resection.

Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection.

Patients with distant metastasis or pathologically non-curative resection after surgical treatment.

Patients who did not know the cancer surveillance interval were not included (*n*=6).

###### 

Effect of Interval of Surveillance Testing on Curative Endoscopic Resection of Early Gastric Cancer

  Cancer surveillance interval   Adjusted odd ratio (95% CI)   *p*-value
  ------------------------------ ----------------------------- -----------
  1 yr                           49.969 (6.340--393.827)       \<0.001
  2 yr                           15.283 (1.833--127.406)       0.012
  Over 2 yr                      10.651 (1.248--90.871)        0.031
  None                           1                             

Age, sex, first degree familial history of stomach cancer, clinically important weight loss, and initial hemoglobin (\<10 g/dL) were adjusted in this multivariate analysis.

Patients who could not remember the cancer surveillance interval were not included (*n*=6).

CI, confidence interval.
